BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 21671479)

  • 1. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
    Choe KS; Haraf DJ; Solanki A; Cohen EE; Seiwert TY; Stenson KM; Blair EA; Portugal L; Villaflor VM; Witt ME; Vokes EE; Salama JK
    Cancer; 2011 Oct; 117(20):4671-8. PubMed ID: 21671479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity.
    Hoebers F; Heemsbergen W; Moor S; Lopez M; Klop M; Tesselaar M; Rasch C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e111-8. PubMed ID: 21362581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
    Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
    Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.
    Sulman EP; Schwartz DL; Le TT; Ang KK; Morrison WH; Rosenthal DI; Ahamad A; Kies M; Glisson B; Weber R; Garden AS
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):399-409. PubMed ID: 18556144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
    Sher DJ; Haddad RI; Norris CM; Posner MR; Wirth LJ; Goguen LA; Annino D; Balboni T; Allen A; Tishler RB
    Cancer; 2010 Oct; 116(20):4761-8. PubMed ID: 20572036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
    Kramer NM; Horwitz EM; Cheng J; Ridge JA; Feigenberg SJ; Cohen RB; Nicolaou N; Sherman EJ; Babb JS; Damsker JA; Langer CJ
    Head Neck; 2005 May; 27(5):406-14. PubMed ID: 15719391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer.
    Unger KR; Lominska CE; Deeken JF; Davidson BJ; Newkirk KA; Gagnon GJ; Hwang J; Slack RS; Noone AM; Harter KW
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1411-9. PubMed ID: 20056341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
    Salama JK; Vokes EE; Chmura SJ; Milano MT; Kao J; Stenson KM; Witt ME; Haraf DJ
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):382-91. PubMed ID: 16213104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.
    Biagioli MC; Harvey M; Roman E; Raez LE; Wolfson AH; Mutyala S; Han HS; Markoe A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1067-73. PubMed ID: 17967302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in patients with recurrent head and neck cancer treated with reirradiation.
    Krstevska V; Tolevska C; Zafirova-Ivanova B; Stojkovski I; Crvenkova S
    J BUON; 2008; 13(3):369-76. PubMed ID: 18979552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
    Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
    Chua DT; Wei WI; Sham JS; Cheng AC; Au G
    Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
    Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
    Kim K; Chie EK; Jang JY; Kim SW; Han SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
    Am J Clin Oncol; 2012 Apr; 35(2):136-40. PubMed ID: 21325937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.